Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd. (KSPHF) Financial Performance & Income Statement Overview
Review Kissei Pharmaceutical Co., Ltd. (KSPHF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Kissei Pharmaceutical Co., Ltd. (KSPHF) Income Statement & Financial Overview
Review Kissei Pharmaceutical Co., Ltd. KSPHF income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $22.66B | $23.20B | $21.30B | $21.16B |
| Cost of Revenue | $11.71B | $11.48B | $10.79B | $10.28B |
| Gross Profit | $10.95B | $11.72B | $10.52B | $10.88B |
| Gross Profit Ratio | $0.48 | $0.51 | $0.49 | $0.51 |
| R&D Expenses | $0.00 | $0.00 | $4.50B | $2.59B |
| SG&A Expenses | $9.41B | $9.26B | $6.39B | $6.14B |
| Operating Expenses | $9.41B | $9.26B | $10.89B | $6.008B |
| Total Costs & Expenses | $21.13B | $20.75B | $21.68B | $19.006B |
| Interest Income | $24.00M | $13.00M | $14.00M | $6.00M |
| Interest Expense | $6.00M | $0.00 | $0.00 | $4.00M |
| Depreciation & Amortization | $1.16B | $1.17B | $1.16B | $1.12B |
| EBITDA | $5.20B | $5.59B | $2.80B | $6.65B |
| EBITDA Ratio | $0.23 | $0.24 | $0.13 | $0.31 |
| Operating Income | $1.54B | $2.46B | -$376.00M | $2.16B |
| Operating Income Ratio | $0.07 | $0.11 | -$0.02 | $0.10 |
| Other Income/Expenses (Net) | $2.50B | $1.96B | $2.01B | $3.36B |
| Income Before Tax | $4.04B | $4.41B | $1.64B | $5.52B |
| Income Before Tax Ratio | $0.18 | $0.19 | $0.08 | $0.26 |
| Income Tax Expense | $915.00M | $811.00M | $490.00M | $1.42B |
| Net Income | $3.12B | $3.59B | $1.14B | $4.11B |
| Net Income Ratio | $0.14 | $0.15 | $0.05 | $0.19 |
| EPS | $72.91 | $82.99 | $25.83 | $92.88 |
| Diluted EPS | $72.91 | $82.99 | $25.83 | $92.88 |
| Weighted Avg Shares Outstanding | $42.81M | $43.27M | $44.24M | $44.21M |
| Weighted Avg Shares Outstanding (Diluted) | $42.81M | $43.27M | $44.24M | $44.21M |
The company's financials show resilient growth, with revenue advancing from $21.16B in Q1 2024 to $22.66B in Q4 2024. Gross profit remained healthy with margins at 48% in Q4 2024 compared to 51% in Q1 2024. Operating income hit $1.54B last quarter, sustaining a consistent 7% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $5.20B. Net income dropped to $3.12B, while earnings per share reached $72.91. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan